- Home
- SNDR vs TERN Comparison
SNDR vs TERN Comparison
Compare SNDR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDR | TERN |
|---|---|---|
| Founded | 1935 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.8B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNDR | TERN |
|---|---|---|
| Price | $32.12 | $52.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $27.83 | ★ $45.22 |
| AVG Volume (30 Days) | 913.6K | ★ 3.5M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 8.04 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $5,674,300,000.00 | N/A |
| Revenue This Year | $5.11 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $276.00 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $20.11 | $2.82 |
| 52 Week High | $33.34 | $53.19 |
Technical Indicators
Market Signals| Indicator | SNDR | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 74.51 |
| Support Level | $26.88 | $52.42 |
| Resistance Level | $33.34 | $53.19 |
| Average True Range (ATR) | 1.29 | 0.07 |
| MACD | 0.02 | -0.31 |
| Stochastic Oscillator | 74.84 | 97.30 |
Price Performance
Historical ComparisonAbout SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, LTL carriers, railroads, ocean carriers, airlines to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload, Intermodal, Logistics and other. It generates maximum revenue from the Truckload segment.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.